Which has preferable earnings & valuation, GKOS or AXGN?

AxoGen has lower revenue, but higher earnings than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 16.71 -$187.69M -$3.28 N/A AxoGen $225.21M 10.61 -$15.70M -$0.64 N/A

Is GKOS or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% AxoGen -13.21% -9.63% -6.26%

Does the media favor GKOS or AXGN?

In the previous week, Glaukos had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Glaukos and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.30 beat Glaukos' score of 0.67 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LQDA or AXGN?

AxoGen has higher revenue and earnings than Liquidia. AxoGen is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.91 -$68.92M $0.14 558.36 AxoGen $225.21M 10.61 -$15.70M -$0.64 N/A

Is LQDA or AXGN more profitable?

Liquidia has a net margin of 7.74% compared to AxoGen's net margin of -13.21%. Liquidia's return on equity of 46.82% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% AxoGen -13.21% -9.63% -6.26%

Does the media favor LQDA or AXGN?

In the previous week, Liquidia had 10 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for Liquidia and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.30 beat Liquidia's score of 0.35 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BLCO or AXGN?

AxoGen has lower revenue, but higher earnings than Bausch + Lomb. AxoGen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch + Lomb $5.10B 1.14 -$360M -$0.62 N/A AxoGen $225.21M 10.61 -$15.70M -$0.64 N/A

Is BLCO or AXGN more profitable?

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% AxoGen -13.21% -9.63% -6.26%

Do analysts prefer AXGN or STVN?

AxoGen currently has a consensus target price of $46.50, suggesting a potential upside of 3.49%. Given AxoGen's higher probable upside, research analysts clearly believe AxoGen is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable earnings & valuation, AXGN or STVN?

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.61 -$15.70M -$0.64 N/A Stevanato Group €1.34B 4.01 €158.21M €0.59 30.15

Does the media refer more to AXGN or STVN?

In the previous week, Stevanato Group had 4 more articles in the media than AxoGen. MarketBeat recorded 7 mentions for Stevanato Group and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.30 beat Stevanato Group's score of -0.31 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AXGN or LIVN?

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.61 -$15.70M -$0.64 N/A LivaNova $1.39B 3.30 -$242.47M $1.95 42.76

Is AXGN or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% LivaNova 7.48% 16.48% 7.59%

Does the media prefer AXGN or LIVN?

In the previous week, AxoGen and AxoGen both had 3 articles in the media. AxoGen's average media sentiment score of 1.30 beat LivaNova's score of 0.72 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AxoGen (AXGN) Competitors

$44.93 +0.44 (+0.99%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$45.34 +0.41 (+0.91%)

As of 06/26/2026 07:58 PM Eastern

Compare

AXGN vs. GKOS, LQDA, BLCO, STVN, and LIVN

Should you buy AxoGen stock or one of its competitors? MarketBeat compares AxoGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AxoGen include Glaukos (GKOS), Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does AxoGen compare to Glaukos?

Glaukos (NYSE:GKOS) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Glaukos presently has a consensus price target of $149.17, suggesting a potential upside of 3.32%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 3.49%. Given AxoGen's higher possible upside, analysts clearly believe AxoGen is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Glaukos has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
AxoGen	-13.21%	-9.63%	-6.26%

In the previous week, Glaukos had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Glaukos and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.30 beat Glaukos' score of 0.67 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has lower revenue, but higher earnings than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	16.71	-$187.69M	-$3.28	N/A
AxoGen	$225.21M	10.61	-$15.70M	-$0.64	N/A

99.0% of Glaukos shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Glaukos beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does AxoGen compare to Liquidia?

Liquidia (NASDAQ:LQDA) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Liquidia has a net margin of 7.74% compared to AxoGen's net margin of -13.21%. Liquidia's return on equity of 46.82% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
AxoGen	-13.21%	-9.63%	-6.26%

In the previous week, Liquidia had 10 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for Liquidia and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.30 beat Liquidia's score of 0.35 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has higher revenue and earnings than Liquidia. AxoGen is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.91	-$68.92M	$0.14	558.36
AxoGen	$225.21M	10.61	-$15.70M	-$0.64	N/A

Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Liquidia currently has a consensus target price of $67.43, suggesting a potential downside of 13.74%. AxoGen has a consensus target price of $46.50, suggesting a potential upside of 3.49%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.90
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Liquidia beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

AxoGen has lower revenue, but higher earnings than Bausch + Lomb. AxoGen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A
AxoGen	$225.21M	10.61	-$15.70M	-$0.64	N/A

Bausch + Lomb presently has a consensus price target of $17.92, suggesting a potential upside of 9.97%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 3.49%. Given Bausch + Lomb's higher probable upside, equities research analysts clearly believe Bausch + Lomb is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
AxoGen	-13.21%	-9.63%	-6.26%

In the previous week, AxoGen had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 3 mentions for AxoGen and 0 mentions for Bausch + Lomb. AxoGen's average media sentiment score of 1.30 beat Bausch + Lomb's score of 0.00 indicating that AxoGen is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Neutral
AxoGen	Positive

Bausch + Lomb has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

AxoGen beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

How does AxoGen compare to Stevanato Group?

AxoGen (NASDAQ:AXGN) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

AxoGen currently has a consensus target price of $46.50, suggesting a potential upside of 3.49%. Given AxoGen's higher probable upside, research analysts clearly believe AxoGen is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

AxoGen has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.61	-$15.70M	-$0.64	N/A
Stevanato Group	€1.34B	4.01	€158.21M	€0.59	30.15

Stevanato Group has a net margin of 11.76% compared to AxoGen's net margin of -13.21%. Stevanato Group's return on equity of 10.27% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Stevanato Group	11.76%	10.27%	6.08%

In the previous week, Stevanato Group had 4 more articles in the media than AxoGen. MarketBeat recorded 7 mentions for Stevanato Group and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.30 beat Stevanato Group's score of -0.31 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Stevanato Group beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

AxoGen (NASDAQ:AXGN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

In the previous week, AxoGen and AxoGen both had 3 articles in the media. AxoGen's average media sentiment score of 1.30 beat LivaNova's score of 0.72 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
LivaNova	7.48%	16.48%	7.59%

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.61	-$15.70M	-$0.64	N/A
LivaNova	$1.39B	3.30	-$242.47M	$1.95	42.76

AxoGen has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

AxoGen presently has a consensus price target of $46.50, indicating a potential upside of 3.49%. LivaNova has a consensus price target of $80.75, indicating a potential downside of 3.16%. Given AxoGen's stronger consensus rating and higher probable upside, equities analysts plainly believe AxoGen is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

80.3% of AxoGen shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AxoGen beats LivaNova on 8 of the 15 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.39B	$7.36B	$7.04B	$12.19B
Dividend Yield	N/A	1.24%	2.66%	6.23%
P/E Ratio	-70.20	51.24	26.13	24.17
Price / Sales	10.61	81.78	556.13	101.82
Price / Cash	N/A	26.44	47.95	55.62
Price / Book	16.10	7.53	10.78	6.36
Net Income	-$15.70M	$159.20M	$3.58B	$337.99M
7 Day Performance	0.20%	1.80%	2.22%	0.10%
1 Month Performance	11.16%	-2.72%	-0.09%	-1.28%
1 Year Performance	327.90%	5.96%	34.39%	27.68%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	2.1008 of 5 stars	$44.93 +1.0%	$46.50 +3.5%	+327.9%	$2.39B	$225.21M	N/A	450	Positive News High Trading Volume
GKOS Glaukos	2.0398 of 5 stars	$130.20 +2.7%	$148.00 +13.7%	+42.3%	$7.45B	$507.44M	N/A	1,094	News Coverage
LQDA Liquidia	2.8091 of 5 stars	$71.80 +0.8%	$60.29 -16.0%	+496.7%	$6.33B	$158.32M	512.89	50	News Coverage Analyst Downgrade Insider Trade
BLCO Bausch + Lomb	2.6527 of 5 stars	$14.99 -0.6%	$17.92 +19.5%	+31.3%	$5.38B	$5.10B	N/A	13,000
STVN Stevanato Group	3.0162 of 5 stars	€16.63 flat	N/A	-27.9%	€5.04B	€1.34B	28.19	6,010

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors